KALV•benzinga•
KalVista Pharma Q3 2025 GAAP EPS $(0.92) Misses $(0.87) Estimate, The Company Had Cash, Cash Equivalents And Marketable Securities Of Approximately $253.2M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 12, 2025 by benzinga